AUTHORS
Asfand Yar Cheema, MD, Mishaal Munir, MD2, Himil Mahadevia, MBBS3, Mahmood Aldapt, M.B.B.S.4, Ali Mushtaq, MBBS5, Atulya Khosla, MBBS6, Aashray Mandala, BS7, Emily Wolf, MD8, Faiz Anwer, MD9, Marwan Shaikh, MD10
AFFILIATIONS
1 Mayo Clinic Florida, Jacksonville, Florida, United States
2 Miami Cancer Institute, Baptist health, Miami, Florida, United States
3 Mayo Clinic Florida, Jacksonville, Florida, United States
4 Mayo Clinic Florida, Jacksonville, Florida, United States
5 Mayo Clinic Florida, Jacksonville, Florida, United States
6 Mayo Clinic Florida, Jacksonville, Florida, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Mayo Clinic Florida, Jacksonville, Florida, United States
9 Mayo Clinic Florida, Jacksonville, Florida, United States
10 Mayo Clinic Florida, Jacksonville, Florida, United States
ABSTRACT
Introduction:
Aplastic anemia (AA) is an immune-mediated bone marrow failure syndrome characterized by pancytopenia, immune dysregulation, and hematopoietic stem cell depletion. Approximately 15% of patients with AA develop secondary myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) due to clonal evolution. Glucagon-like peptide-1 receptor agonists (GLP-1a), primarily indicated for glycemic control, have demonstrated anti-inflammatory and antineoplastic properties in preclinical studies through inhibition of the PI3K/AKT/mTOR, ERK/MAPK, NF-κB, and NLRP3 inflammasome pathways. These actions lead to reduced oxidative stress, cytokine suppression, and cell-cycle arrest, potentially mitigating immune-mediated marrow injury and limiting clonal progression in AA. Given these mechanistic insights, we evaluated the impact of GLP-1a therapy on clinical outcomes in patients with AA using a large real-world database.
Methods:
We conducted a retrospective, propensity score-matched (PSM) cohort study using the TriNetX Analytics Network database. Our analysis included Aplastic anemia patients with (n=1,726) and without (n=83,344) GLP-1a therapy between 2010 and 2022. PSM (1:1) was applied using a greedy nearest-neighbor method with a caliper of 0.1 pooled standard deviations, adjusting for demographics, AA-directed therapy, comorbidities, laboratory parameters, and cardiovascular medications. Primary outcomes were all-cause mortality, Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and venous thromboembolism (VTE). Secondary outcomes included hospitalizations, ICU admissions, acute kidney injury (AKI), and heart failure (HF). Outcomes were compared using odds ratios (ORs) with 95% confidence intervals (CIs) over a 3-year follow-up period.
Results:
After PSM, 1,669 matched pairs (mean age 57.4 ± 15.4 years for GLP-1a users and mean age 50.9 ± 20.3 years for non-users, male-to-female ratio 0.62) were analyzed. The mean duration of GLP-1a therapy among users was 268.33 ± 225.50 days. GLP-1a therapy was associated with significantly lower odds of all-cause mortality (OR 0.286, 95% (0.238, 0.345, p<0.001), MDS (OR 0.470, 95% CI 0.369, 0.599, p<0.001), AML (OR 0.393, 95% CI 0.276, 0.559, p<0.001), ischemic stroke/TIA (OR 0.765, 95% CI 0.610, 0.961, p=0.021), and VTE (OR 0.540, 95% CI 0.444, 0.657, p<0.001). Additionally, GLP- 1a users demonstrated reduced odds of all-cause hospitalizations (OR 0.320, 95% CI 0.275, 0.373, p<0.001), ICU admissions (OR 0.319, 95% CI 0.266, 0.382, p<0.001), AKI (OR: 0.393, 95% CI: 0.339, 0.455,p <0.001), and HF (OR 0.548, 95% CI 0.471, 0.638, p<0.001)
Conclusion:
In this large, real-world, propensity-matched cohort study, GLP-1a therapy in AA patients was associated with significantly lower risks of all-cause mortality, MDS, AML, ischemic stroke/TIA, venous thromboembolism, and HF. GLP-1a use was also linked to reduced health care utilization, including all-cause hospitalizations and ICU admissions. While the observational nature and limited clinical granularity of the dataset preclude causal inference, these findings support a compelling rationale for prospective randomized controlled trials to evaluate GLP-1a as a disease-modifying adjunct in AA management.
DISCLOSURES
Asfand Yar Cheema, MD: No relevant conflicts of interest to declare.